Lundbeck Seattle BioPharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio

Lundbeck Seattle BioPharmaceuticals (US): 1 reconciled FDA prescription therapies, $34.7M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$34.7M
2024 Medicare Part D Spend$15.1M
2024 Medicaid Spend$19.7M
California HCAI SB 17 Filings5 WAC filings (max 21.0% 2-yr change)